Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from dolutegravir-based therapy to darunavir/cobicistat-based therapy for weight gain in adults with HIV
2019-004620-38Phase 4Terminated
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Triumeq continuation, Switch to Rezolsta + Kivexa and Switch to Symtuza (3 arms). Primary endpoint: Percentage of individuals with significant reduction in weight at week 48. Started Feb 2020; status: terminated.
02
Drugs
abacavirdarunavir + cobicistatabacavir + lamivudinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-004620-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004620-38.